These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 9120953)

  • 1. Re: Editorial: can prostate specific antigen derivatives reduce the frequency of unnecessary prostate biopsies?
    Stephan C; Lein M; Jung K; Schnorr D; Loening SA
    J Urol; 1997 Apr; 157(4):1371. PubMed ID: 9120953
    [No Abstract]   [Full Text] [Related]  

  • 2. Can prostate specific antigen derivatives reduce the frequency of unnecessary prostate biopsies?
    Klein EA
    J Urol; 1996 Aug; 156(2 Pt 1):443-4. PubMed ID: 8683698
    [No Abstract]   [Full Text] [Related]  

  • 3. Optimal predictors of prostate cancer on repeat prostate biopsy: a prospective study of 1,051 men.
    Djavan B; Zlotta A; Remzi M; Ghawidel K; Basharkhah A; Schulman CC; Marberger M
    J Urol; 2000 Apr; 163(4):1144-8; discussion 1148-9. PubMed ID: 10737484
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Prognostic significance of prostate-specific antigen in defining indications for initial prostate biopsy].
    Popov SV; Guseinov RG; Skryabin ON; Orlov IN; Martov AG
    Urologiia; 2018 Jul; (3):92-97. PubMed ID: 30035426
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transurethral biopsy of the prostate for persistently elevated or increasing prostate specific antigen following multiple negative transrectal biopsies.
    Rovner ES; Schanne FJ; Malkowicz SB; Wein AJ
    J Urol; 1997 Jul; 158(1):138-41; discussion 141-2. PubMed ID: 9186340
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Frequency of Unnecessarily Biopsies among Patients with Suspicion of Prostate Cancer in Syrian Men.
    Bachour DM; Chahin E; Al-Fahoum S
    Asian Pac J Cancer Prev; 2015; 16(14):5967-70. PubMed ID: 26320481
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Comment on Grond, A., M. Ostermann-Myrau: Benign and malignant diseases of the prostate].
    Grond A
    Versicherungsmedizin; 1995 Apr; 47(2):66-7. PubMed ID: 7539193
    [No Abstract]   [Full Text] [Related]  

  • 8. Relationship of chronic histologic prostatic inflammation in biopsy specimens with serum isoform [-2]proPSA (p2PSA), %p2PSA, and prostate health index in men with a total prostate-specific antigen of 4-10 ng/ml and normal digital rectal examination.
    Lazzeri M; Abrate A; Lughezzani G; Gadda GM; Freschi M; Mistretta F; Lista G; Fossati N; Larcher A; Kinzikeeva E; Buffi N; Dell'Acqua V; Bini V; Montorsi F; Guazzoni G
    Urology; 2014 Mar; 83(3):606-12. PubMed ID: 24315305
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of PSA density of transition zone as a potential parameter in reducing the number of unnecessary prostate biopsies in patients with psa levels between 2.6 and 10.0 ng/mL.
    Castro HAS; Iared W; Santos JEM; Solha RS; Shigueoka DC; Ajzen SA
    Int Braz J Urol; 2018; 44(4):709-716. PubMed ID: 29697929
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Differential diagnostic value of prostate-specific antigen in prostatic hyperplasia].
    Maksimov VA; Kamalov AA; Karpov VK; Riaboĭ AV; Prokhorov AV
    Urologiia; 2001; (2):37-40. PubMed ID: 11490716
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Early detection of prostatic carcinoma: Is PSA screening suitable?].
    Kaulen H
    Dtsch Med Wochenschr; 2003 May; 128(18):977. PubMed ID: 12755136
    [No Abstract]   [Full Text] [Related]  

  • 12. Correlation between immunohistochemical patterns and serum levels of PSA and PSAP in prostatic pathology: evaluation of 198 prostatic fine needle biopsies.
    Vitali A; Ardoino S; Durante P; Ferro MA; Li Causi F; Parodi C; Sanguineti G; Gaffuri M; Paerachino M; Salvadori RP
    Anticancer Res; 1994; 14(4A):1503-7. PubMed ID: 7526771
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long term prostate-specific antigen trends following subcapsular prostatectomy.
    Klausner AP; Anderson BB; Espy PG; Despradel VM; Grob BM
    Can J Urol; 2010 Dec; 17(6):5442-6. PubMed ID: 21172107
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Comparison in the follow-up of two patients with persistent elevated PSA and negative prostate biopsy].
    Sciarra A; Panebianco V
    Urologia; 2014; 81(1):60-3. PubMed ID: 24585440
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prostate specific antigen and prostate specific antigen density. Roles in patient evaluation and management.
    Benson MC; Olsson CA
    Cancer; 1994 Sep; 74(6):1667-73. PubMed ID: 7521783
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incidental prostatic cancer: repeat TURP or biopsy?
    Martino P; Palazzo S; Battaglia M; Lucarelli G; Selvaggi FP
    Urol Int; 2004; 73(3):193-7. PubMed ID: 15539835
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Re: Free and complexed prostate specific antigen in the differentiation of benign prostatic hyperplasia and prostate cancer: studies in serum and plasma samples.
    Lein M; Jung K; Brux B; Knäbich A; Sinha P; Schnorr D; Loening SA
    J Urol; 1999 Aug; 162(2):502-3. PubMed ID: 10411077
    [No Abstract]   [Full Text] [Related]  

  • 18. Minimum prostate-specific antigen (PSA) level diagnostic of prostate cancer.
    Yesner R; Kelly LJ; Chan YK
    Conn Med; 1996 Jul; 60(7):399-404. PubMed ID: 8758658
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Present-day possibilities of prostate cancer screening in patients with benign prostatic hyperplasia before and after surgical treatment].
    Pushkar' DIu; Rasner PI; Skobelev PP
    Urologiia; 2001; (6):48-54. PubMed ID: 11785083
    [No Abstract]   [Full Text] [Related]  

  • 20. PSA scores: should we use a lower threshold?
    Carter HB
    Johns Hopkins Med Lett Health After 50; 2004 Oct; 17(8):6. PubMed ID: 15602780
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.